Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans

Dasatinib monohydrate indicated for the treatment of chronic myeloid leukemia displays pH-dependent solubility. The aim of reported development program of novel dasatinib anhydrate containing formulation was to demonstrate improved absorption and lower pharmacokinetic variability compared to dasatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Jiří, Bartůněk, Aleš, Hauser, Tomáš, Sedmak, Gregor, Beránek, Josef, Ryšánek, Pavel, Šíma, Martin, Slanař, Ondřej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681895/
https://www.ncbi.nlm.nih.gov/pubmed/37789147
http://dx.doi.org/10.1038/s41375-023-02045-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681895/
https://www.ncbi.nlm.nih.gov/pubmed/37789147
http://dx.doi.org/10.1038/s41375-023-02045-1

Ejemplares similares